Compare Biocon Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ASTRAZENECA PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ASTRAZENECA PHARMA BIOCON /
ASTRAZENECA PHARMA
 
P/E (TTM) x 30.2 121.6 24.8% View Chart
P/BV x 3.9 35.6 10.9% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    ASTRAZENECA PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
ASTRAZENECA PHARMA
Mar-18
BIOCON /
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs7071,278 55.3%   
Low Rs554883 62.7%   
Sales per share (Unadj.) Rs91.9228.4 40.2%  
Earnings per share (Unadj.) Rs16.710.4 161.2%  
Cash flow per share (Unadj.) Rs24.216.3 148.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.698.8 102.9%  
Shares outstanding (eoy) m600.0025.00 2,400.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.7 145.1%   
Avg P/E ratio x37.7104.2 36.2%  
P/CF ratio (eoy) x26.166.4 39.3%  
Price / Book Value ratio x6.210.9 56.7%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,33027,008 1,400.8%   
No. of employees `0006.11.4 452.1%   
Total wages/salary Rs m11,6531,535 759.0%   
Avg. sales/employee Rs Th8,994.34,210.9 213.6%   
Avg. wages/employee Rs Th1,900.71,132.2 167.9%   
Avg. net profit/employee Rs Th1,635.3191.1 855.8%   
INCOME DATA
Net Sales Rs m55,1445,710 965.7%  
Other income Rs m1,444123 1,178.8%   
Total revenues Rs m56,5885,833 970.2%   
Gross profit Rs m15,883463 3,431.2%  
Depreciation Rs m4,478147 3,038.0%   
Interest Rs m7090-   
Profit before tax Rs m12,140438 2,771.7%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123179 1,186.7%   
Profit after tax Rs m10,026259 3,869.5%  
Gross profit margin %28.88.1 355.3%  
Effective tax rate %17.540.8 42.8%   
Net profit margin %18.24.5 400.7%  
BALANCE SHEET DATA
Current assets Rs m48,2283,209 1,502.8%   
Current liabilities Rs m30,3762,070 1,467.8%   
Net working cap to sales %32.420.0 162.2%  
Current ratio x1.61.6 102.4%  
Inventory Days Days6872 94.4%  
Debtors Days Days8635 244.9%  
Net fixed assets Rs m64,130790 8,114.6%   
Share capital Rs m3,00050 6,000.0%   
"Free" reserves Rs m57,9802,419 2,396.6%   
Net worth Rs m60,9802,469 2,469.5%   
Long term debt Rs m15,7660-   
Total assets Rs m121,9244,605 2,647.4%  
Interest coverage x18.1NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 36.5%   
Return on assets %8.85.6 156.5%  
Return on equity %16.410.5 156.7%  
Return on capital %16.817.7 94.5%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,506300 5,176.4%   
Fx outflow Rs m10,3992,015 516.1%   
Net fx Rs m5,107-1,715 -297.7%   
CASH FLOW
From Operations Rs m11,54688 13,135.4%  
From Investments Rs m-7,138-94 7,626.1%  
From Financial Activity Rs m-2,417NA-  
Net Cashflow Rs m2,103-6 -36,894.7%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 15.7 68.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 12,856 855.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

MoD Approves Defence Purchases, Vedanta's Delisting, and Top Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a positive note on Friday. Benchmark indices edged higher as positive developments in a coronavirus vaccine trial improved global risk sentiment.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 3, 2020 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS